Description
The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 receptors, but this is mechanistically implausible for a bacterial organism. The mechanism by which a gut bacterium could traverse the BBB and the actual source of GLP-1 receptor binding remains unexplained.
Gap type: unexplained_observation Source paper: Engineered Clostridium butyricum-pMTL007-GLP-1 Delays Neurodegeneration in Prnp-SNCA*A53T Transgenic Mice Model by Suppressing Astrocyte Senescence. (2026, Probiotics and antimicrobial proteins, PMID:40627051)
Resolution criteria
Gap resolved when: (1) Mechanistic studies demonstrate whether gut-derived GLP-1 (not the bacterium itself) crosses the BBB via receptor-mediated transcytosis, peripheral vagal signaling, or systemic circulation acting on circumventricular GLP-1R, using ≥2 orthogonal tracing methods (fluorescent GLP-1 analogs, in situ hybridization); (2) Blood-brain barrier permeability assays (TEER measurements in hCMEC/D3 cells, n≥6) confirm that intact bacterial cells cannot cross, validating indirect GLP-1 signaling as the mechanism; (3) GLP-1R antagonist (exendin-9) abrogates neuroprotective effects in the bacterial treatment group, confirming receptor dependency (AUC difference ≥20%, p<0.05); (4) The revised mechanistic model is published with quantitative PK data linking gut GLP-1 secretion to brain GLP-1R occupancy ≥10%.